Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Retained Earnings (2022 - 2025)

Historic Retained Earnings for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$707.5 million.

  • BioXcel Therapeutics' Retained Earnings fell 1066.9% to -$707.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$707.5 million, marking a year-over-year decrease of 1066.9%. This contributed to the annual value of -$650.2 million for FY2024, which is 1009.13% down from last year.
  • As of Q3 2025, BioXcel Therapeutics' Retained Earnings stood at -$707.5 million, which was down 1066.9% from -$676.6 million recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Retained Earnings high stood at -$277.3 million for Q1 2022, and its period low was -$707.5 million during Q3 2025.
  • Over the past 4 years, BioXcel Therapeutics' median Retained Earnings value was -$590.6 million (recorded in 2023), while the average stood at -$538.4 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 6747.49% in 2023, then crashed by 648.89% in 2025.
  • BioXcel Therapeutics' Retained Earnings (Quarter) stood at -$411.5 million in 2022, then plummeted by 43.51% to -$590.6 million in 2023, then decreased by 10.09% to -$650.2 million in 2024, then dropped by 8.82% to -$707.5 million in 2025.
  • Its Retained Earnings stands at -$707.5 million for Q3 2025, versus -$676.6 million for Q2 2025 and -$657.5 million for Q1 2025.